他汀类药物使用及其强度对颈动脉内膜切除术后卒中和心肌梗死的影响
基于OptumLabs数据仓库2004至2014年21277例颈动脉内膜切除术患者,分析他汀使用时长与强度对术后卒中和心肌梗死的影响。术后他汀使用与30天和90天卒中风险降低相关,对远期卒中和心肌梗死有独立保护作用;高强度他汀与标准治疗相比未显示对30天和90天结局的影响。
要点
- 术后他汀使用与30天卒中风险降低相关(OR 0.77,95%CI 0.61-0.98,P=.036)。
- 术后他汀使用与90天卒中风险降低相关(OR 0.75,95%CI 0.62-0.90,P=.002)。
- 高强度他汀与标准治疗相比,30天和90天卒中及心肌梗死结局无显著差异。
核心结论
- 颈动脉内膜切除术后他汀使用与30天和90天卒中风险降低相关,并对远期心肌梗死和卒中具有独立保护作用。
- 与标准治疗相比,高强度他汀使用未显示对颈动脉内膜切除术后30天和90天卒中或心肌梗死结局的影响。
研究设计与样本
- 使用OptumLabs数据仓库(包含理赔和临床信息的纵向真实世界数据集)分析颈动脉内膜切除术后卒中、心肌梗死和他汀使用率。
- 研究纳入2004年至2014年接受颈动脉内膜切除术的21277例患者,平均年龄70岁,男性占59.4%,平均Elixhauser指数评分4.2,随访中位时间2.4年(范围0.2-10.0年)。
- 研究考察了他汀治疗的时长和强度。
主要发现
- 长期他汀使用见于57.4%的患者;他汀分布包括阿托伐他汀35%、辛伐他汀35%、普伐他汀11%、瑞舒伐他汀10%和洛伐他汀7%。
- 30天和90天卒中率分别为1.3%和2.2%,心肌梗死率分别为0.5%和1.1%。
- 术后他汀使用与30天卒中率降低相关(OR 0.77,95%CI 0.61-0.98,P=.036),与90天卒中率降低相关(OR 0.75,95%CI 0.62-0.90,P=.002)。
- 术后他汀使用对30天心肌梗死率(OR 1.01,95%CI 0.69-1.46,P=.975)或90天心肌梗死率(OR 0.85,95%CI 0.66-1.11,P=.213)未显示保护效应。
- 高强度他汀与标准治疗相比,对30天卒中结局(OR 0.96,95%CI 0.60-1.5,P=.847)、90天卒中结局(OR 1.06,95%CI 0.74-1.5,P=.762)、30天心肌梗死(OR 0.81,95%CI 0.39-1.68,P=.576)或90天心肌梗死(OR 1.25,95%CI 0.79-1.96,P=.339)均无影响。
临床怎么用
- 原文结论指出颈动脉内膜切除术后他汀使用与30天和90天卒中风险降低相关,并对远期心肌梗死和卒中具有保护作用。
- 原文结论指出与标准治疗相比,高强度他汀使用未显示对术后30天和90天卒中或心肌梗死结局的影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Statin use in patients with cerebrovascular disease undergoing carotid endarterectomy (CEA) has been advocated for prevention of stroke and cardiovascular events. However, the effect of statin therapy on long-term outcomes after CEA still needs to be delineated. METHODS: OptumLabs Data Warehouse, a comprehensive, longitudinal, real-world dataset with deidentified lives across claims and clinical information, was used to analyze the rates of stroke, myocardial infarction (MI), and statin use after CEA. Both duration and intensity of statin therapy were investigated. RESULTS: There were 21,277 patients who underwent CEA from 2004 to 2014. The average age was 70 years, and 59.4% were male. The average Elixhauser index score was 4.2. Follow-up was a median of 2.4 years (range, 0.2-10.0 years). Long-term statin use was observed in 57.4%. Statin distribution included atorvastatin 35%, simvastatin 35%, pravastatin 11%, rosuvastatin 10%, and lovastatin 7%. The 30- and 90-day stroke rates were 1.3% and 2.2%, and the MI rates were 0.5% and 1.1%, respectively. Postoperative statin use was associated with a lower perioperative stroke rate at 30 days (odds ratio [OR], 0.77; 95% confidence interval [CI], 0.61-0.98; P = .036) and 90 days (OR, 0.75; 95% CI, 0.62-0.90; P = .002). Postoperative statin use did not show a protective effect on 30-day or 90-day MI rates (OR, 1.01; 95% CI, 0.69-1.46; P = .975) or 90-day MI rates (OR, 0.85; 95% CI, 0.66-1.11; P = .213). High-intensity statin use when compared with standard therapy did not affect 30-day stroke outcomes (OR, 0.96; 95% CI, 0.60-1.5; P = .847) or 90-day stroke outcomes (OR, 1.06; 95% CI, 0.74-1.5; P = .762); or 30-day MI (OR, 0.81; 95% CI, 0.39-1.68; P = .576) or 90-day MI (OR, 1.25; 95% CI, 0.79-1.96; P = .339). Statin use was independently protective against long-term stroke (hazard ratio, 0.82; 95% CI, 0.75-0.91; P < .001) and MI (hazard ratio, 0.83; 95% CI, 0.75-.92; P < .001). CONCLUSIONS: Postoperative statin use among patients undergoing CEA was associated with a decreased risk of stroke at 30 and 90 days, as well as a long-term protective effect against MI and stroke. High-intensity statin use compared with standard use did not show an effect on outcomes of stroke or MI at 30 and 90-days after CEA.
引用
- Arinze N, Farber A, Sachs T, et al. The effect of statin use and intensity on stroke and myocardial infarction after carotid endarterectomy. J Vasc Surg. 2018. PMID: 29685507. doi:10.1016/j.jvs.2018.02.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。